Ipsen unveiled the €52 million ($49.9 million) expansion it made into its active pharmaceutical ingredient manufacturing facility in Blanchardstown, a small suburb of Dublin. The investment is aimed at boosting medicine and ingredient production in the cancer and rare disease space.

The enhanced site, which has a staff of 175, has already enabled Ipsen Ireland's R&D and manufacturing teams to scale their active pharmaceutical ingredient production by 10% this year compared to 2021.

The company said the investment supported the extension and acceleration of vital medicine production.

Its products help patients suffering from both niche cancers and rare diseases in Ireland and across international markets.

Ipsen also plans a further €15m of capital investment in its Blanchardstown site between 2023 and 2026 which will facilitate continued site enhancement from a technology and sustainability perspective.